

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製葯(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

UPDATED INFORMATION OF THE GROUP'S PRODUCT

This announcement is made by Dawnrays Pharmaceutical (Holdings) Limited (the "Company") on a voluntary basis to keep shareholders and potential investors informed of the latest development of the Company and its subsidiaries (collectively referred to as the "Group").

The board of directors of the Company (the "Board") is pleased to announce that "Cetirizine Hydrochloride Tablets 10mg", (brand name "Xikewei" 「西可韋」), an anti-allergic drug of Suzhou Dawnrays Pharmaceutical Co., Ltd., a subsidiary of the Group ("Suzhou Dawnrays"), has been granted approval by National Medical Products Administration for passing the consistency of quality and efficacy evaluation of generic drugs (the "Consistence Evaluation").

As a significant reform and regulatory initiative introduced by the State Council and the National Medical Products Administration in the recent years, the Consistence Evaluation fundamentally ensures that all the generic drugs will truly be of the same quality standard and efficacy as their counterparts originally produced by international pharmaceutical companies, solidly safeguarding the treatment quality and thus the health of the public.

With the effect of selective histamine H1 receptor antagonist, cetirizine hydrochloride is an anti-allergic drug commonly used for symptomatic treatment of allergy-related syndromes of diseases such as seasonal rhinitis, perennial allergic rhinitis, allergic conjunctivitis, pruritus caused by allergies and urticaria. The renowned quality of "Xikewei" (西可韋), a product of the Group, has been highly recognized by clinical doctors and patients since the product launch in 1998.

**for identification purpose only*

The newly obtained approval on Consistence Evaluation is not only a further recognition of the Group's long-term commitment of "Quality First" as well as the quality and efficacy of product, but also a momentum for further market expansion accelerating the progress of substituting originally created medicines and thus providing patients with a choice of economical medicines of quality.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 02 January 2020

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; and three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.